I only look at fundamentals
This is very tough surgical procedure to learn -- most eye docs won't attempt it. GKOS has competition as well in this new type of surgery. Not going to be a fast grower.
I am more inclined to a gene therapy company like AGTC -- which made a very nice partnership with Biogen. Lots of potential and good science team.
EYES also very interesting -- good people and a big lead in technology.
Ophthalmic research -- 16 years.
This is not an easy field to understand. You really have to be in it on a daily basis.
Now that we have so many public companies in the eyecare sectors, a lot of people are just getting interested in analyzing these stocks.
There are a lot of flukey ideas out there that sound good when you hear them but really have very little chance of success. People are pushing out IPOs to take advantage on the interest in the sector and the profits made in stocks like REGN and OPHT.
I would say be very cautious of anything that sounds too good, like an eyedrop or pill for retinal diseases. Or an EYEG drug delivery concept.
But ITEK looks like it is the real deal and $5 a share was a total steal.
In the ophthalmics field, dry eye drugs fail in phase 3 and so do AMD drugs -- glaucoma is a much safer bet given the free pass the FDA has provided to ITEK.
The author really doesn't comprehend the flaws in AER and the strong competitor (Anakem) in the rho kinase category.
Finally, the ITEK IPO was drastically underpriced -- should have come at $14 or so.
As I have mentioned before, ITEK can now sell international rights for a big number. No question.
PVA was for a long time averaging about 1,000 barrels of oil per day from its new wells.
Recently, we are seeing about a third of that production from many new wells, which is strange because a smaller drilling program should be focused on the best acreage.
Can this drop in initial production all be because the company is managing its wells for longer life?
Or have the best prospects already been drilled.
I would really like to know because production and reserve life is going to determine the value of PVA's assets.
Maybe we should all chip in for his gold watch.
After all, he's done such a great job taking PVA from 18 to under 2.
I'm sure the earnings release is going to praise him because this has become a tone deaf company.
Too many dummies who never heard of ITEK a week ago and are now spouting off cluelessly.
Takeover talk is premature -- ITEK added three big guns to the management team just in the past week. You think they signed up for a three-month gig. ITEK needs to stay independent at least through the phase 3.
No need for a secondary, either. The FDA gave ITEK a golden ticket that skyrocketed the value of the international rights to traodenosen.
If you want to see an overpriced stock in the ophthalmic sector, it's not ITEK.
Look at EYEG -- what retina doc really wants to bring iontopheresis drug delivery (electric stimulation through the skin) into their clinic?
AERI also has a major competitor in the rho kinase category -- privately held Anakem.
The Anakem drug may be better than Rhopressa -- no hyperemia.
Do your homework.
Hey genius, ITEK can sell the international rights to their drug (plus milestone payments and future royalties) for about $200 million -- right now they can do this.
All you people yelling for a secondary are clueless about this industry.
International partner an easy deal now.
Probably the next big step for ITEK and the money will be significant.
(So don't count on a secondary to knock the stock down)
You can do a partnership at any time -- and ITEK is in a good position to do one now.
Of course you can't sell anything yet.
ITEK sold themselves cheap doing an IPO at 6 -- they had indicated they wanted to do it much higher.
Still a lot to like here.
I think ITEK can easily get a partner now for the international rights to the drug.
Maybe $150-$200 million from a partner and they won't need to sell more shares to fund the big tphase 3 trial.
I took a nice profit this am but will come back in on any dip to 7.50
Analysts comments should be very positive but the profit was too good to pass up.